11 JUNE 2020

GFN

Welcome to GFN 2020 - why we are doing this & Plenary 1

-

To be filmed together; Gerry to encourage ANESVAP donations

Welcome message

David Sweanor

Welcome

David Sweanor

Gerry Stimson

Welcome

Gerry Stimson

Perspectives: setting the scene

-

Where are we now and how did we get here?
Mark Tyndall

Tobacco harm reduction: ensuring we learn lessons from history

Mark Tyndall

Clarisse Virgino

The threat of prohibition: consumers as collateral damage?

Clarisse Virgino

Will Godfrey

Responsible journalism: holding the media to account

Will Godfrey

Marewa Glover

Why science should always trump ideology

Marewa Glover

Clive Bates

What's gone wrong?

Clive Bates

Q&A time

-

Virtual Coffee Break

-

Nicotine: science, ethics and human rights

-

Why it is important to ensure science is key, voices are heard and the rights of the vulnerable are safeguarded?
Ethan Nadelmann

Reflections on the issues raised by panellists

Ethan Nadelmann

Fiona Patten

What or who should guide the political agenda?

Fiona Patten

John Oyston

The importance of a patient-centred approach

John Oyston

Moira Gilchrist

Can a leopard change its spots?

Moira Gilchrist

Samrat Chowdhery

Policy, state control and the tobacco monopoly

Samrat Chowdhery

Greg Conley

Powerful forces not always benign

Greg Conley

Ethan Nadelmann

Introduction to the session

Ethan Nadelmann

Virtual Coffee Break

-

Michael Russell Oration 2020

-

Gerry Stimson

Concluding remarks

Gerry Stimson

Louise Ross

Pragmatism versus dogma: freeing the inner vaper in smokers

Louise Ross

Gerry Stimson

Introduction to the Michael Russell Oration

Gerry Stimson

12 JUNE 2020

GFN - Part 2

Introduction

-

Gerry Stimson

Gerry Stimson

COVID-19 and other epidemics: the challenges for THR science

-

Why it is critical that science both leads and supports policy and regulation
Roberto Sussman

Nicotine use: the consequences of bad science for consumers

Roberto Sussman

Pini Matzner

Advanced analytics for the public good: using big data to detect pandemics and outbreaks

Pini Matzner

Konstantinos Farsalinos

Unforeseen circumstances: nicotine, COVID-19 and the ACE2 receptor

Konstantinos Farsalinos

Riccardo Polosa

Smoking, vaping and COVID 19: what does the science tell us?

Riccardo Polosa

Caitlin Notley

Introduction

Caitlin Notley

Q&A time

-

Virtual Coffee Break

-

Tobacco harm reduction: taking stock on regulation

-

Shane MacGuill

Linked destinies? Evolving legal cannabis regulation and the interplay with e-vapour market

Shane MacGuill

Abrie du Plessis

The upcoming Conference of the Parties of the WHO FCTC and the EU Tobacco Products Directive revision

Abrie du Plessis

Marina Foltea

Demystifying the right to health in the context of e-vapour markets regulation

Marina Foltea

Patricia Kovacevic

Accelerating tobacco harm reduction via regulatory and economics measures

Patricia Kovacevic

Tim Phillips

How the 2019 US developments will impact the global vape market for many years to come

Tim Phillips

Marina Foltea

Introduction

Marina Foltea

Virtual Coffee Break

-

Tobacco harm reduction: costs and benefits

-

Who can access alternatives to smoking, what are the barriers? Some examples here of the importance of universal access
Gerry Stimson

Closing remarks

Gerry Stimson

Chimwemwe Ngoma

Safer nicotine: changing perceptions and lives in a tobacco-driven economy

Chimwemwe Ngoma

Sree Sucharitha

Safer nicotine: the potential for change in developing communities

Sree Sucharitha

Spike Babaian

Untapped potential: vape shops a health resource

Spike Babaian

Alex Wodak

How investment can pay a significant health and social dividend

Alex Wodak

Kevin Mcgirr

Introduction

Kevin Mcgirr